Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 16/20 | 1.00 |
| ▸ | AURKA | O14965 | 8/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.61 |
| ▸ | CD38 | P28907 | 3/20 | 0.52 |
| ▸ | AKT1 | P31749 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054636 | 0.89 | RPS6KB1 (0.80) | RPS6KB1AURKAAURKB | |
| SCHEMBL15055432 | 0.88 | RPS6KB1 (0.79) | RPS6KB1AURKAAURKBAKT1 | |
| SCHEMBL15073590 | 0.83 | RPS6KB1 (0.75) | RPS6KB1AURKAAURKBAKT1 | |
| SCHEMBL15054406 | 0.82 | RPS6KB1 (1.00) | RPS6KB1AURKAAURKBAKT1 | |
| SCHEMBL15055215 | 0.82 | RPS6KB1 (1.00) | RPS6KB1AURKAAURKBAKT1 | |
| SCHEMBL15055368 | 0.80 | RPS6KB1 (1.00) | RPS6KB1AURKAAURKBCD38AKT1 | |
| SCHEMBL15073443 | 0.79 | RPS6KB1 (1.00) | RPS6KB1AURKAAURKBCD38AKT1 | |
| SCHEMBL15054623 | 0.77 | RPS6KB1 (0.70) | RPS6KB1AURKAAURKBCD38AKT1 | |
| SCHEMBL664356 | 0.76 | RPS6KB1 (1.00) | RPS6KB1AURKAAURKB | |
| SCHEMBL27947200 | 0.75 | RPS6KB1 (0.58) | RPS6KB1AURKAAURKBCD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | claimed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | claimed |
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| CN-104169258-B | novel heterocyclic carboxamides as modulators of kinase activity | 默克专利有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-2794571-B1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2794571-B1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| US-9139568-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9139568-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9139568-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| EP-2794571-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| WO-2013096194-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096194-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | RPS6KB1 237/4885AURKA 118/4885AURKB 159/4885 |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MAP3K19, MAP3K15, MAP3K12 | RPS6KB1 210/4885AURKA 158/4885AURKB 173/4885 |
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MAP3K15, MAP3K12, MAP3K11 | RPS6KB1 197/4885AURKA 184/4885AURKB 194/4885 |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | RPS6KB1 210/4885AURKA 158/4885AURKB 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.